Difference between revisions of "Team:Lethbridge HS/Results"

 
(6 intermediate revisions by 2 users not shown)
Line 11: Line 11:
 
         (Written by Florian Albrecht)
 
         (Written by Florian Albrecht)
 
         Shoutout to the 2016 U of C wiki */
 
         Shoutout to the 2016 U of C wiki */
−
 
+
t
 
       /* Start general reset ================================================== */
 
       /* Start general reset ================================================== */
 
         html body {font-size: inherit;font-family: inherit;background-color: transparent;color: inherit;padding: 0;}
 
         html body {font-size: inherit;font-family: inherit;background-color: transparent;color: inherit;padding: 0;}
Line 907: Line 907:
  
 
<div class="col-md-12">
 
<div class="col-md-12">
−
<h3>sample title 1</h3>
+
 
 
<a name="first"></a>
 
<a name="first"></a>
−
<p>The half clot time of different treatments on the blood was tested and calculated. Specifically, the clotting time of our blood was tested with 70mg of heparin as well as 71mg of heparin in different trials, in addition to either 1mL or 2mL of PNRA or 1mL or 2mL of our construct in order to determine the effects of our construct on the blood clotting pathway. A positive control was also set by having blood with heparin with no cells, to ensure the blood did not spontaneously clot on its own. In general, we were able to show that our construct caused the blood to clot. Although these are preliminary tests, we plan to optimize our construct further in the future in order to determine the resulting flow rates after our construct is applied to ensure that it does not impact the rate of blood flow throughout the rest of the patient’s body.
+
 
 +
<img src="https://static.igem.org/mediawiki/2016/a/a4/T%E2%80%94lethbridgehs--graph_and.jpeg" width="100%">
 +
 
 +
 
 +
        <table class="table table-striped table-bordered">
 +
                                           
 +
                                            <caption>Clot Times</caption>
 +
                                            <thead>
 +
                                                <tr>
 +
                                                    <th>Treatment</th>
 +
                                                    <th>Time</th>
 +
<th>Half Clot Time</th>
 +
                                                </tr>
 +
                                            </thead>
 +
                                            <tbody>
 +
                                                <tr>
 +
                                                    <td>70 mg heparin blood, 1 mL viper construct</td>
 +
                                                    <td>0</td>
 +
<td>31</td>
 +
                                                </tr>
 +
                                                <tr>
 +
                                                    <td>
 +
70 mg heparin blood, 1 mL PNRa
 +
</td>
 +
                                                    <td>1</td>
 +
<td>33</td>
 +
                                                </tr>
 +
                                                <tr>
 +
                                                    <td>
 +
70 mg heparin blood, 2 mL PNRA
 +
</td>
 +
                                                    <td>2</td>
 +
  <td>41</td>
 +
                                                </tr>
 +
                                                <tr>
 +
                                                    <td>
 +
70 mg heparin blood, 2 mL viper construct
 +
</td>
 +
                                                    <td>3</td>
 +
<td>54</td>
 +
                                                </tr>
 +
                                                <tr>
 +
                                                    <td>
 +
70 mg heparin blood, 0 cells
 +
</td>
 +
                                                    <td>4</td>
 +
<td>44</td>
 +
                                                </tr>
 +
                                                <tr>
 +
                                                    <td>
 +
71 mg heparin blood, 2 mL PNRA
 +
</td>
 +
                                                    <td>5</td>
 +
<td>57</td>
 +
                                                </tr>
 +
 
 +
<tr>
 +
                                                    <td>
 +
 
 +
71 mg heparin blood, 1 mL viper construct
 +
 
 +
</td>
 +
                                                    <td>6</td>
 +
<td>67</td>
 +
                                                </tr>
 +
 
 +
<tr>
 +
                                                    <td>
 +
 
 +
71 mg heparin blood, no cells
 +
 
 +
</td>
 +
                                                    <td>7</td>
 +
<td>48</td>
 +
                                                </tr>
 +
 
 +
                                            </tbody>
 +
                                        </table>
 +
 
 +
<img src="https://static.igem.org/mediawiki/2016/5/55/T%E2%80%94lethbridgehs--bloodpics_and.jpeg" width="60%">
 +
<p><br>The half clot time of different treatments on the blood was tested and calculated. Specifically, the clotting time of our blood was tested with 70mg of heparin as well as 71mg of heparin in different trials, in addition to either 1mL or 2mL of PNRA or 1mL or 2mL of our construct in order to determine the effects of our construct on the blood clotting pathway. A positive control was also set by having blood with heparin with no cells, to ensure the blood did not spontaneously clot on its own. In general, we were able to show that our construct caused the blood to clot. Although these are preliminary tests, we plan to optimize our construct further in the future in order to determine the resulting flow rates after our construct is applied to ensure that it does not impact the rate of blood flow throughout the rest of the patient’s body.</br>
 
</p>
 
</p>
−
<h3>sample title 1</h3>
 
−
<p>"At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga. Et harum quidem rerum facilis est et expedita distinctio. Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet ut et voluptates repudiandae sint et molestiae non recusandae. Itaque earum rerum hic tenetur a sapiente delectus, ut aut reiciendis voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat."</p>
 
−
<h3>sample title 1</h3>
 
−
<a name="second"></a>
 
−
<p>"At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga. Et harum quidem rerum facilis est et expedita distinctio. Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet ut et voluptates repudiandae sint et molestiae non recusandae. Itaque earum rerum hic tenetur a sapiente delectus, ut aut reiciendis voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat."</p>
 
 
</div>
 
</div>
  

Latest revision as of 03:55, 20 October 2016

Lethbridge HS iGEM 2016

RESULTS

Clot Times
Treatment Time Half Clot Time
70 mg heparin blood, 1 mL viper construct 0 31
70 mg heparin blood, 1 mL PNRa 1 33
70 mg heparin blood, 2 mL PNRA 2 41
70 mg heparin blood, 2 mL viper construct 3 54
70 mg heparin blood, 0 cells 4 44
71 mg heparin blood, 2 mL PNRA 5 57
71 mg heparin blood, 1 mL viper construct 6 67
71 mg heparin blood, no cells 7 48


The half clot time of different treatments on the blood was tested and calculated. Specifically, the clotting time of our blood was tested with 70mg of heparin as well as 71mg of heparin in different trials, in addition to either 1mL or 2mL of PNRA or 1mL or 2mL of our construct in order to determine the effects of our construct on the blood clotting pathway. A positive control was also set by having blood with heparin with no cells, to ensure the blood did not spontaneously clot on its own. In general, we were able to show that our construct caused the blood to clot. Although these are preliminary tests, we plan to optimize our construct further in the future in order to determine the resulting flow rates after our construct is applied to ensure that it does not impact the rate of blood flow throughout the rest of the patient’s body.